Rejoni
Bedford, US · Founded 2020 · Delaware corporation · 21 employees on LinkedIn · 7 known investors
Find your way into Rejoni
168 people in our graph share verified history with the Rejoni team — schools, employers, funds. One of them is your warm intro.
Todd Kleinunlockedknows Amar Sawhney · together at The University of Texas at Austin (overlapped)
×7knows the team · via The University of Texas at Austin
knows the team · via Axtria - Ingenious Insights
×3knows the team · via Cybernetix Ventures
Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.
Founders & leadership
Rejoni was founded in 2020 by AMARPREET SAWHNEY and Amar Sawhney.
AS
AMARPREET SAWHNEYinCo-founder · CEOAmarpreet Sawhney holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi. He is CEO of Rejoni, which develops products to prevent adhesions following gynecological interventions, and also leads Instylla and Pramand, companies developing liquid embolics and surgical sealing products respectively; previously he served as President and CEO of Ocular Therapeutix and founded multiple medical device companies including Confluent Surgical and Focal.
AS
Amar SawhneyinFounderAmarpreet Sawhney holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. from IIT Delhi; he previously served as President and CEO of Ocular Therapeutix (NASDAQ: OCUL) and founded multiple medical device companies including Confluent Surgical, Focal Inc., and Access Closure Inc., several of which were acquired by larger healthcare firms.
NS
NICK SVENCERNamed on SEC filing
FK
FARHAD KHOSRAVINamed on SEC filing
Board
TB
TARA BUTLERBoard director
Investors · 7
Funding
SEC filings, press & company announcements$66.3M disclosed across 3 of 4 rounds · 2020–2026
- $25MraisedJun 2026 · 2 sourcesSource ↗
▶$26.3MraisedOct 2023 · 22 investors · BiotechnologyRule 506(b)
▶$26.3MraisedOct 2023 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guneesh BatraDirector
- Amarpreet SawhneyExecutive Officer, Director
- Nicholas SvencerExecutive Officer, Director
- Farhad KhosraviDirector
- Offering amount
- $26.3M
- Amount sold
- $26.3M
- Minimum investment
- $10K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedSep 2020 · 20 investors · BiotechnologyRule 506(b)
▶$15MraisedSep 2020 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- AMARPREET SAWHNEYExecutive Officer, Director, Promoter
- NICK SVENCERExecutive Officer, Director, Promoter
- TARA BUTLERExecutive Officer, Director, Promoter
- FARHAD KHOSRAVIExecutive Officer, Director, Promoter
- Offering amount
- $15M
- Amount sold
- $15M
- Minimum investment
- $20K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Rejoni do?
- Rejoni is a company focused on uterine health, developing technology to address women's reproductive and gynecological health needs.
- Who founded Rejoni?
- Rejoni was founded by AMARPREET SAWHNEY, Amar Sawhney in 2020.
- Who are Rejoni's investors?
- Rejoni's investors include Ascension Ventures, ClavystBio, Delos Capital, FemHealth Ventures, Iyengar Capital Partners, Amed Ventures, Catalyst Health Ventures.
- How much funding has Rejoni raised?
- Rejoni has disclosed $66.3M raised across 3 of its 4 known rounds.
- Where is Rejoni headquartered?
- Rejoni is headquartered in Bedford, US.